Central nervous system neoplasm – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Sat, 20 Jun 2026 04:03:13 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Central nervous system neoplasm – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study to Find the Right Dose and Safety of Lutetium (177Lu) Edotreotide and Arginine-Lysine in Children with Somatostatin Receptor-Positive Tumors https://clinicaltrials.eu/trial/study-to-find-the-right-dose-and-safety-of-lutetium-177lu-edotreotide-and-arginine-lysine-in-children-with-somatostatin-receptor-positive-tumors/ Wed, 29 Apr 2026 15:03:43 +0000 https://clinicaltrials.eu/trial/study-to-find-the-right-dose-and-safety-of-lutetium-177lu-edotreotide-and-arginine-lysine-in-children-with-somatostatin-receptor-positive-tumors/ This clinical trial is focused on studying the treatment of children with somatostatin receptor-positive tumors, which are a type of solid tumor or lymphoma that shows a specific marker called the somatostatin receptor. These tumors can include various types such as neuroendocrine tumors, lymphoma, and central nervous system tumors. The treatment being tested is called lutetium Lu 177 edotreotide, a targeted radiopharmaceutical therapy. This therapy involves using a radioactive substance to target and treat the tumors. Additionally, an arginine-lysine solution is used to support the treatment process.

The purpose of the study is to determine the appropriate dose of lutetium Lu 177 edotreotide for children, based on its safety and how it moves through the body. The study will involve giving the treatment to participants and monitoring them to see how their bodies respond. This includes checking for any side effects and measuring how the treatment is absorbed by the body. The study will also look at how effective the treatment is in reducing the size of the tumors.

Participants in the study will receive the treatment through an intravenous infusion, which means it will be given directly into a vein. The study will take place over several cycles, with regular check-ups to monitor the participants’ health and the progress of the treatment. The goal is to find the safest and most effective dose for treating these types of tumors in children. The study is expected to continue for several years to gather enough information to make informed decisions about the treatment’s use in the future.

]]> Study of Gadobutrol for MRI in Adults with Cerebrospinal Fluid Disorders, Including Hydrocephalus and Brain Tumors https://clinicaltrials.eu/trial/study-of-gadobutrol-for-mri-in-adults-with-cerebrospinal-fluid-disorders-including-hydrocephalus-and-brain-tumors/ Wed, 29 Apr 2026 15:02:48 +0000 https://clinicaltrials.eu/trial/study-of-gadobutrol-for-mri-in-adults-with-cerebrospinal-fluid-disorders-including-hydrocephalus-and-brain-tumors/ This clinical trial is focused on studying several conditions related to the brain and spinal fluid, including communicating hydrocephalus, primary malignant brain tumor, intracranial cysts, Chiari malformation, idiopathic intracranial hypotension, idiopathic intracranial hypertension, and conditions following a subarachnoid hemorrhage. The study uses a special type of MRI (magnetic resonance imaging) contrast agent called gadobutrol, which is a gadolinium-based contrast agent (GBCA). This agent is administered into the spinal canal to help visualize the flow and clearance of fluids in the brain.

The purpose of the study is to better understand how the contrast agent moves within the brain. This helps in assessing where there might be blockages in the flow of cerebrospinal fluid and how quickly substances are cleared from the brain. Participants will receive the contrast agent through a procedure called intrathecal use, which means it is injected into the space around the spinal cord. After the injection, MRI scans will be performed to track the distribution and intensity of the contrast agent over time.

The study aims to provide valuable insights into the treatment and management of these brain and spinal fluid conditions by observing changes in the MRI signal after the contrast is administered. This information could potentially lead to improved diagnostic and therapeutic strategies for patients with these conditions.

]]> Study on APL-101 for Treating Advanced Solid Tumors and Non-Small Cell Lung Cancer with MET Changes in Patients https://clinicaltrials.eu/trial/study-on-apl-101-for-treating-advanced-solid-tumors-and-non-small-cell-lung-cancer-with-met-changes-in-patients/ Wed, 29 Apr 2026 15:01:37 +0000 https://clinicaltrials.eu/trial/study-on-apl-101-for-treating-advanced-solid-tumors-and-non-small-cell-lung-cancer-with-met-changes-in-patients/ This clinical trial is focused on studying the treatment of certain types of cancer using a medication called APL-101, also known as Bozitinib. The diseases being studied include advanced solid tumors and Non-Small Cell Lung Cancer (NSCLC) that have specific changes in a gene called MET. These changes can include MET Exon 14 skipping mutations, MET amplification, and MET fusion. The study also looks at tumors in the central nervous system (CNS) with MET alterations and other solid tumors with overexpression of HGF and MET. The purpose of the study is to evaluate the safety and effectiveness of APL-101 in treating these conditions.

Participants in the study will receive APL-101 in the form of a capsule taken by mouth. The study will be conducted in two phases. The first phase has already been completed and focused on understanding the safety and how the body processes the drug. The second phase will focus on how well APL-101 works as a treatment on its own for the cancers mentioned, and also as an additional treatment for NSCLC that has developed resistance to other treatments. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects of APL-101.

The study will involve regular check-ups and assessments to monitor the participants’ health and the effects of the treatment. This includes measuring the size of tumors and checking for any side effects. The goal is to find the best dose of APL-101 and to see how effective it is in treating these specific types of cancer. Participants will be closely monitored throughout the study to ensure their safety and to gather important information about the treatment’s impact on their condition.

]]> Study on the Effects of Selpercatinib in Children with Advanced RET-Altered Solid Tumors or Primary Central Nervous System Tumors https://clinicaltrials.eu/trial/study-on-the-effects-of-selpercatinib-in-children-with-advanced-ret-altered-solid-tumors-or-primary-central-nervous-system-tumors/ Wed, 29 Apr 2026 14:28:18 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-selpercatinib-in-children-with-advanced-ret-altered-solid-tumors-or-primary-central-nervous-system-tumors/ This clinical trial is focused on studying the effects of a medication called Selpercatinib in children and young adults with advanced tumors. These tumors are either solid or located in the central nervous system, such as the brain or spinal cord, and have a specific change in their genes known as RET-altered. The purpose of the study is to understand how safe the medication is and how well it works in treating these types of tumors.

The study is divided into two phases. In the first phase, the main goal is to determine the safety of Selpercatinib and identify any side effects that might occur. In the second phase, the focus is on evaluating how well the tumors respond to the treatment. This involves measuring the size of the tumors to see if they shrink or disappear after taking the medication. The study will involve taking Selpercatinib in different forms, such as tablets or oral solutions, and it will be administered by mouth.

Participants in the study will be monitored closely to track their response to the treatment and any side effects they may experience. The study aims to provide valuable information on the potential benefits and risks of using Selpercatinib for treating these specific types of tumors in young patients. The trial is expected to continue until late 2024, with the hope of finding an effective treatment option for those affected by these challenging conditions.

]]> Study on Larotrectinib for Treating Children with Advanced Solid Tumors with NTRK Fusion https://clinicaltrials.eu/trial/study-on-larotrectinib-for-treating-children-with-advanced-solid-tumors-with-ntrk-fusion/ Wed, 29 Apr 2026 14:25:54 +0000 https://clinicaltrials.eu/trial/study-on-larotrectinib-for-treating-children-with-advanced-solid-tumors-with-ntrk-fusion/ This clinical trial is focused on studying the effects of a medication called larotrectinib in children with certain types of tumors. These tumors are known as solid tumors that have a specific genetic change called NTRK fusion. The study aims to test the safety and effectiveness of larotrectinib in treating these tumors. Larotrectinib is taken by mouth, either as a capsule or an oral solution.

The purpose of the study is to understand how safe larotrectinib is for children and how well it works in shrinking or controlling the tumors. The study is divided into two phases. In the first phase, the focus is on determining the safety of the medication and identifying any side effects. In the second phase, the study looks at how well the tumors respond to the treatment, which means checking if the tumors get smaller or stop growing.

Participants in the study will receive larotrectinib and will be monitored by healthcare professionals to observe any changes in their condition. The study will help gather important information about the potential benefits and risks of using larotrectinib for treating tumors with NTRK fusion in children. This research is important for developing new treatments for these types of tumors and improving the care of children affected by them.

]]>